GSK Stock GSK (GSK, $48.96) was a top quarterly gainer, rising +23.89%

GET DAILY SIGNALS

Get AI intraday signals

GSK - GSK plc

Loading...

Price: $48.96

Daily change: +$0.11 (+0.23%)

Daily volume: 1.1M

3-month price change: +$9.44 (+23.89%)

Capitalization: $98.9B

Industry: Pharmaceuticals: Major

GSK (GSK, $48.96) was one of top quarterly gainers, jumping +2 to $48.96 per share. A.I.dvisor analyzed 62 stocks in the Pharmaceuticals: Major Industry over the last three months, and discovered that of them (7) charted an Uptrend while of them (2) trended down.

Momentum Indicator for GSK turns positive, indicating new upward trend

GSK saw its Momentum Indicator move above the 0 level on December 19, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 68 similar instances where the indicator turned positive. In of the 68 cases, the stock moved higher in the following days. The odds of a move higher are at .

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GSK advanced for three days, in of 337 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 266 cases where GSK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 59 cases where GSK's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GSK declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

GSK broke above its upper Bollinger Band on December 03, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.527) is normal, around the industry mean (9.054). P/E Ratio (13.622) is within average values for comparable stocks, (24.434). Projected Growth (PEG Ratio) (0.418) is also within normal values, averaging (2.056). Dividend Yield (0.034) settles around the average of (0.026) among similar stocks. P/S Ratio (2.329) is also within normal values, averaging (3.759).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 74, placing this stock slightly better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. GSK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.